Please login to the form below
Zarzio
This page shows the latest Zarzio news and features for those working in and with pharma, biotech and healthcare.
Clock ticking on biosimilar Enbrel in US
In markets outsider the US - where it is known as Zarzio and has been available since 2006 - Sandoz' drug has captured around a 30% share of the Neupogen market.
Latest news
-
Novartis launches first biosimilar Zarxio in the US
therapies.”. Biosimilars have been available in Europe since 2006 and Zarxio is already available in more than 40 countries under the brand name Zarzio, where it has captured around 30% of
-
Apotex latest to file Neupogen biosimilar in the US
the brand name Zarzio.
-
FDA close to first biosimilar approval
US under the brand name Zarzio.
-
Biosimilars could make EU big cost savings after slow start
In the case of Amgen's once-daily white blood cell stimulator Neupogen (filgrastim), however, the drug has now been overtaken by its biosimilar rivals - led by Sandoz' Zarzio - and the
-
FDA 'must publish biosimilar naming guide soon'
as Zarzio - in Europe in 2009. ... According to the company Zarzio is the leading G-CSF in Europe with a 30 per cent market share.
More from news
Approximately 1 fully matching, plus 7 partially matching documents found.
Featured jobs
-
Principal Medical Writer
-
£48 - 58, 000 according to skills and experience benefits
- Account Manager– Medical Communications
-
(Negotiable - depending on experience)
- Director of Scientific Services, Medical Communications, Six fig...
-
Six figure salary
- Account Director, Medical Communications & Events
-
£50 - 65, 000 according to skills and experience benefits
- Senior Medical Writer, MedComms Agency
-
Salary TBC
-
Vice President
-
Competitive Salary Offered
-
Consultant
-
competitive salary
- Account Director or Senior Account Director
-
Salary TBC
Subscribe to our email news alerts
- Novartis links up with NHS for speedy access to cholesterol drug inclisiran
- Genital herpes vaccine candidate heads for human studies
- Bayer bulks up in women’s health again with non-hormonal contraceptive deal
- FDA starts priority review of BMS Opdivo/Yervoy in first-line NSCLC
- Pfizer signs $507m cancer deal with Effector Therapeutics
- Key success factor (KSF)
- How do companies prepare for reimbursement?
- Lucid Group adds more magic to the mix with four new hires
- Communiqué Awards 2020 is now open for entry
- Novo Nordisk gets MACE prevention claim for Ozempic in US
- NICE leaves the ‘the NHS door’ open despite rejecting Bayer’s Vitrakvi
- FDA committee rejects Intellipharmaceutics’ opioid drug Aximris
PMHub
CSafe Global
CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...
Latest intelligence
- How do companies prepare for reimbursement?
- Valid Insight explore how to optimise your market access strategy during new product development, how to address payer concerns and prepare for reimbursement....
- Integrating electronic health records into clinical trials
- How organisations are working to realise the research potential of EHRs...
- Keeping up the fight against HIV and using the lessons to tackle other threats
- Danny Buckland interviews Gilead’s Mike Elliott...
Quick links
Infographics
